HC Wainwright & Co. Reiterates Buy on Innate Pharma, Maintains $11.5 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterated a Buy rating on Innate Pharma (NASDAQ:IPHA) and maintained a price target of $11.5.
March 22, 2024 | 10:26 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Innate Pharma's stock rating was reiterated as Buy by HC Wainwright & Co. with a price target of $11.5.
The reiteration of a Buy rating and maintenance of a price target by a reputable analyst firm like HC Wainwright & Co. typically signals confidence in the company's future performance, potentially leading to positive investor sentiment and an upward movement in the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100